Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer
Status:
Unknown status
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The present project will follow our previous phaseⅡ study of FOLFOX regimens for the
treatment of stage Ⅳ colorectal cancer. We will recruit at least 200 patients for this study.
The selection of patients will be based on rigorous eligibility criteria. The patients will
be allocated based on the expression of each molecular marker (MSI, TS, DPD, MVD and EGFR)
and the implementation of chemotherapy. For example, in the examination for the clinical
implications of EGFR, the patients will be classified into four groups: EGFR（＋）
chemotherapy（＋）; EGFR（＋） chemotherapy（-）; EGFR（-） chemotherapy（＋）; EGFR（-） chemotherapy（-）.
Base on the analysis of this 2×2 table, we will clarify the prognostic significance of a
specific molecular marker is due to whether the specific molecular marker predicts biological
invasiveness and/or chemosensitivity. We believe the present study will have the following
significance: （1）To further clarify the mechanisms for the carcinogenesis and progression of
CRC; （2）To facilitate the development of novel chemotherapeutic agents; and （3） To gain the
experience for the practice of evidence-based medicine.